NYSE:NNVC NanoViricides Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.04 -0.07 (-3.32%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$2.04▼$2.1950-Day Range$1.12▼$2.6052-Week Range$1.04▼$7.86Volume39,794 shsAverage Volume33,050 shsMarket Capitalization$23.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address NNVC Stock Forecast (MarketRank)Overall MarketRank™0.13 out of 5 starsMedical Sector1373rd out of 1,411 stocksPharmaceutical Preparations Industry660th out of 672 stocksAnalyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for NanoViricides. Previous Next 0.0 Community Rank Outperform VotesNanoViricides has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNanoViricides has received 17 “underperform” votes. (Add your “underperform” vote.)Community SentimentNanoViricides has received 100.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NanoViricides and other stocks. Vote “Outperform” if you believe NNVC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NNVC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of NanoViricides is held by insiders.Percentage Held by InstitutionsOnly 9.59% of the stock of NanoViricides is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NanoViricides (NYSE:NNVC)NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.Read More NNVC Stock News HeadlinesJune 18, 2022 | americanbankingnews.comNanoViricides (NYSE:NNVC) Now Covered by Analysts at StockNews.comJune 9, 2022 | americanbankingnews.comNanoViricides (NYSE:NNVC) Receives New Coverage from Analysts at StockNews.comJune 1, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC)May 26, 2022 | nasdaq.comPre-market Movers: NTNX, WKME, SNOW, ISPC, NNVC…See More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees17Year FoundedN/ACompany Calendar Last Earnings5/17/2022Today6/26/2022Fiscal Year End6/30/2022Profitability EPS (Most Recent Fiscal Year)($0.740010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.70% Return on Assets-30.16% Debt Debt-to-Equity RatioN/A Current Ratio41.21 Quick Ratio41.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.78Miscellaneous Outstanding Shares11,550,000Free Float11,069,000Market Cap$23.56 million OptionableOptionable Beta1.03 NanoViricides Frequently Asked Questions How has NanoViricides' stock price performed in 2022? NanoViricides' stock was trading at $2.11 at the beginning of the year. Since then, NNVC stock has decreased by 3.3% and is now trading at $2.04. View the best growth stocks for 2022 here. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) announced its earnings results on Tuesday, May, 17th. The company reported ($0.16) earnings per share for the quarter. View NanoViricides' earnings history. Who are NanoViricides' key executives? NanoViricides' management team includes the following people: Dr. Anil R. Diwan Ph.D., Exec. Chairman, Pres, CEO & Sec. (Age 63, Pay $400k)Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA, Chief Financial Officer (Age 63, Pay $129.6k)Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 75) Who are some of NanoViricides' key competitors? Some companies that are related to NanoViricides include Annovis Bio (ANVS), GT Biopharma (GTBP), NervGen Pharma (NGENF), Adagene (ADAG), TherapeuticsMD (TXMD), Endo International (ENDP), Trevi Therapeutics (TRVI), Ardelyx (ARDX), Alzamend Neuro (ALZN), Enlivex Therapeutics (ENLV), MEI Pharma (MEIP), Tiziana Life Sciences (TLSA), Synlogic (SYBX), Vicapsys Life Sciences (VICP) and Merrimack Pharmaceuticals (MACK). View all of NNVC's competitors. What is NanoViricides' stock symbol? NanoViricides trades on the New York Stock Exchange (NYSE) under the ticker symbol "NNVC." How do I buy shares of NanoViricides? Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NanoViricides' stock price today? One share of NNVC stock can currently be purchased for approximately $2.04. How much money does NanoViricides make? NanoViricides (NYSE:NNVC) has a market capitalization of $23.56 million. The company earns $-8.82 million in net income (profit) each year or ($0.740010) on an earnings per share basis. How many employees does NanoViricides have? NanoViricides employs 17 workers across the globe. How can I contact NanoViricides? NanoViricides' mailing address is 1 Controls Dr, Shelton, Connecticut 06484-6153. The official website for NanoViricides is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at [email protected], or via fax at 203-859-5095. This page (NYSE:NNVC) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here